Genomma Lab stock sets October 21 earnings date

Published on 10/06/2026 at 17:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genomma Lab stock is priced at MXN 12.530 on October 5, 2026, ahead of its October 21 results. Q2 revenue rose 4.9 percent sequentially, while net income fell 24.2 percent.

Genomma Lab, MX01LA010006, Illustration mit AI erstellt.

Genomma Lab (ISIN MX01LA010006) was last at MXN 12.530 on the BMV on October 5, 2026, as investors approach the company's next quarterly report. Morningstar reported on October 1, 2026, that Genomma Lab will publish third quarter 2026 results on October 21, after the Mexican Stock Exchange closes.

October 21 marks the next test

The scheduled release is the clearest near-term checkpoint for the pharmaceutical and personal care products company. Genomma Lab will hold its earnings call on October 22, 2026, at 11:00 a.m. Mexico City time, according to Morningstar.

The release date matters because the latest reported quarter showed stronger sales but weaker bottom-line performance. Genomma Lab's Q2 2026 revenue was MXN 4,397.037 million, compared with MXN 4,190.623 million in Q1, an increase of 4.9 percent, while net income decreased from MXN 494.647 million to MXN 374.493 million, a decline of 24.2 percent, according to Investing.com.

Profit conversion remains central

The Q2 figures put the emphasis on profit conversion rather than sales alone. Q2 diluted earnings per share were MXN 0.370 against a consensus estimate of MXN 0.460, a shortfall of MXN 0.090, while the reported net profit margin was 8.52 percent, according to Yahoo Finance.

Operating cash flow provides a second measure for the October review. Genomma Lab generated MXN 383.158 million from operations in Q2 2026 and reported free cash flow of MXN 262.988 million for the quarter in the standardized financial statements.

Consensus target stays above the share price

The analyst picture remains more optimistic than the latest BMV quotation. Investing.com lists a Buy consensus from six analysts, including four Buy ratings and two Hold ratings, with an average 12-month target of MXN 21.667, a low target of MXN 16 and a high target of MXN 29.

Against the MXN 12.530 BMV price on October 5, 2026, the average target lies 72.9 percent above the share price. That gap is a valuation expectation, not a company forecast, and the Q3 report will provide the next operating test for the consensus view.

Genomma Lab stock heads toward its results date

Genomma Lab stock has a defined calendar marker in October: Q3 2026 results on October 21, 2026, followed by the conference call on October 22. The BMV quotation, Q2 earnings conversion and analyst target gap give investors three measurable reference points for the report.